Skip to main content

Table 1 Demographic and clinical characteristics of patients at baseline

From: Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

Characteristic

Age group

Total

 

< 60 years

60 to 64 years

> 64 years

 

Cases

   Total

3,160 (100)

645 (100)

422 (100)

4,227 (100)

Receptor status (ER-positive and/or PgR-positive versus both negative)

   Positive

1,941 (61.4)

447 (69.3)

278 (65.9)

2,666 (63.1)

   Negative

876 (27.7)

144 (22.3)

112 (26.5)

1,132 (28.6)

   Unknown

343 (10.9)

54 (8.4)

32 (7.6)

429 (10.1)

Tumor grading

   Grade 1

142 (5.1)

29 (5.0)

22 (5.8)

193 (5.2)

   Grade 2

1,534 (54.9)

321 (55.6)

224 (59.4)

2,079 (55.5)

   Grade 3

1,117 (40.0)

227 (39.3)

131 (34.7)

1,475 (39.4)

   Valid

2,793 (88.4)

577 (89.5)

377 (89.3)

3,747 (88.6)

   Missing

367 (11.6)

68 (10.5)

45 (10.7)

480 (11.4)

Histological tumor type

   Ductal invasive

2,405 (76.1)

459 (71.1)

315 (74.6)

3,179 (75.2)

   Lobular invasive

477 (15.0)

127 (19.6)

65 (15.4)

669 (15.8)

   Other

233 (7.3)

54 (8.3)

35 (8.2)

322 (7.6)

   Valid

3,115 (98.6)

640 (99.9)

415 (98.4)

4,170 (98.7)

   Missing

45 (1.4)

5 (0.1)

7 (1.6)

57 (1.3)

Surgery type

   Breast-conserving

1935 (61.2)

381 (59.0)

228 (54.0)

2,544 (60.1)

   Mastectomy

961 (30.4)

216 (33.4)

161 (38.1)

1,338 (31.6)

   Valid

2,896 (91.6)

597 (92.5)

389 (92.1)

3,882 (91.8)

   Missing

264 (8.3)

48 (7.4)

33 (7.8)

345 (8.1)

Age median (years)

47

62

67

51

Age range (years)

23 to 59

60 to 64

65 to 80

23 to 80

  1. Data presented as n (%). All percentage values are valid. ER, estrogen receptor; PgR, progesterone receptor.